Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy Bannerji, R., Brown, J. R., Advani, R. H., Arnason, J., O'Brien, S. M., Allan, J. N., Chavez, J. C., Barnes, J. A., Joyce, R., Ansell, S., Topp, M. S., Adriaens, L., Ufkin, M., Kostic, A., Paccaly, A., Gao, B., Trail, P. A., Lowy, I., Brownstein, C. AMER SOC HEMATOLOGY. 2016

View details for Web of Science ID 000394446804024